+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 2Years - 17Years
All Genders
ID05491525

Long-term Study of Vibegron in Children Ages 2 to Under 18 With Neurogenic Detrusor Overactivity Using Clean Intermittent Catheterization

Led by Urovant Sciences GmbH · Updated on 2026-06-15

71

Participants Needed

38

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety, effectiveness, and how the body processes Vibegron in children aged 2 to less than 18 years who have neurogenic detrusor overactivity NDO and regularly use clean intermittent catheterization CIC. This open-label trial aims to better understand Vibegrons impact on this pediatric population over a long-term period. Participants receive Vibegron orally once daily, with doses adjusted based on their weight. The study has two parts Part A where doses may be reduced up to two times based on individual responses and safety, and Part B where participants receive a dose selected by a safety monitoring board based on data from Part A. Participants are grouped into cohorts according to weight ranges. Throughout the study, participants undergo assessments including bladder function tests and questionnaires measuring incontinence and symptom severity. Researchers monitor changes in bladder capacity, detrusor activity, catheterized volumes, leakage episodes, and quality of life over approximately 52 weeks. Safety and drug processing are continuously evaluated, with the study expected to complete around September 2030.

CONDITIONS

Brief Title

Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

Research Team

S

Study Director

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here